Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model

• Những tác giả chính: Philip J. Kuehl (Tác giả), Marcie J. Grimes (Tác giả), Devon Dubose (Tác giả), Michael Burke (Tác giả), David A. Revelli (Tác giả), Andrew P. Gigliotti (Tác giả), Steven A. Belinsky (Tác giả), Mathewos Tessema (Tác giả)
• Định dạng: Sách
• Được phát hành: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Những chủ đề: article
• Truy cập trực tuyến: Connect to this object online.

Intravenous (IV) topotecan is approved for the treatment of various malignancies including lung cancer but its clinical use is greatly undermined by severe hematopoietic toxicity. We hypothesized that inhalation delivery of topotecan would increase local exposure and efficacy against lung cancer whi...